GlassScriptPhysician profile
Krushangi Patel
NPI 1912266339
$7,470.32
in general payments reported to CMS, 2019-2025
57 companies · $253 in 2025
The $253 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2021: $235 · 2022: $3,105 · 2023: $3,433 · 2024: $29.11 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,404 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.61 |
| Education | $310.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $534.44 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $504.16 | 2021-2023 | Imfinzi, Lynparza, Enhertu |
| Amgen INC. | $473.21 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Astellas Pharma US INC | $457.31 | 2019-2023 | Padcev, Xospata |
| Seagen INC. | $434.14 | 2022-2023 | Tukysa, Adcetris |
| Celgene Corporation | $340.66 | 2022-2023 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $277.36 | 2019-2023 | Verzenio, Jaypirca |
| Takeda Pharmaceuticals U.S.A., INC. | $266.99 | 2019-2023 | Alunbrig, Ninlaro |
| Pfizer INC. | $258.81 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $235.06 | 2021-2023 | Opdivo, Opdualag |
| Myriad Genetic Laboratories, INC. | $226.62 | 2022-2023 | Precisetumor, Myrisk |
| Merck Sharp & Dohme LLC | $216.65 | 2022-2023 | Keytruda, Lynparza |
| Genzyme Corporation | $197.24 | 2022-2023 | |
| Eisai INC. | $191.64 | 2021-2023 | |
| Janssen Biotech, INC. | $186.26 | 2022-2023 | Darzalex, Imbruvica |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krushangi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.